Streetbeat News

ZLDPF

Zealand Pharma A/S.

https://www.zealandpharma.com/

CEO

Emmanuel Dulac

Employees

355

Industry

Pharmaceutical Preparation Manufacturing

Open

106.00

Mkt cap

6.7B

Volume

200

High

106.00

P/E Ratio

-39.76

52-wk high

141.74

Low

94.24

Div yield

N/A

52-wk low

46.59

Zealand Pharma A/S (ZLDPF) reported a Q3 loss of $0.56 per share, which was better than the Zacks Consensus Estimate of a $0.62 loss. However, this is a decline from last year's earnings of $0.18 per share.

Portfolio Pulse from

November 07, 2024 | 1:30 pm

Zealand Pharma plans to start a phase 2b trial for its obesity drug candidate, petrelintide, in Q4 2024.

Portfolio Pulse from

November 07, 2024 | 6:45 am

Novo Nordisk and Eli Lilly, leaders in the obesity drug market, may face competition from 16 new drugs expected by 2029. Despite their current dominance, new entrants like Roche, Pfizer, and Amgen could shift market dynamics. Analysts suggest Novo and Lilly stocks might be overvalued due to potential market changes.

Portfolio Pulse from Vandana Singh

October 11, 2024 | 6:11 pm

The iShares MSCI EAFE Small-Cap ETF (NASDAQ:SCZ) has reached a 52-week high, driven by strong performance in small-cap stocks from developed markets outside North America. The ETF has risen 6.33% year-to-date and 12.84% over the past year, benefiting from its diversified portfolio and bullish momentum.

Portfolio Pulse from Surbhi Jain

August 22, 2024 | 7:34 pm

Zealand Pharma announced positive Phase 1b trial results for its weight management drug, petrelintide, showing significant weight loss and good tolerability. This news comes as the weight-loss drug market, dominated by Novo Nordisk's Ozempic and WeGovy, is projected to grow significantly.

Portfolio Pulse from Benzinga Neuro

June 21, 2024 | 12:12 pm

Zealand Pharma has reported data from part 1 of its multiple ascending dose trial with ZP8396 for obesity. The results showed a mean weight loss of 5.3% and 5.1% at 0.6 and 1.2 mg doses respectively, compared to 2.6%, 3.6%, and 4.2% at doses of 0.7, 1.4, and 2.4 mg doses.

Portfolio Pulse from Benzinga Newsdesk

July 03, 2023 | 10:08 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.